Ignite Creation Date:
2024-05-06 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05690698
Status:
COMPLETED
Last Update Posted:
2023-08-30
First Post:
2022-12-28
Brief Title:
Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium
Sponsor:
Alexandria University
Organization:
Alexandria University
Study Overview
Official Title:
Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium
Status:
COMPLETED
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In population of intensive care unit ICU most studies compared atypical antipsychotics such as quetiapine with the traditional haloperidol in delirious patients of various forms and etiologies The role of such agents in patients with hyperactive is not fully understood
This study compares the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on morbidity length of stay in the intensive care unit and mortality in critically ill patients
This study compares the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on morbidity length of stay in the intensive care unit and mortality in critically ill patients
Detailed Description:
A common complication in the intensive care unit ICU that has recently been identified is delirium Defining delirium as a sudden deterioration in attention awareness and cognition which is not explained by any pre-existing neurocognitive disorder but because of another medical condition the Diagnostic and Statistical Manual of Mental Disorders DSM-V clarified the definition of delirium
A dibenzothiazepine derivative with a novel and distinctive pharmacologic profile is quetiapine The limbic system is overactive in delirium which is one of its pathophysiologies By obstructing the mesolimbic dopamine D2 receptors specifically quetiapine may be able to regulate this hyperactivity
The objective of this study is to compare the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on morbidity length of stay in ICU and mortality in critically ill patients
This research will not receive any grants funding or financial aid NOT FUNDED STUDY Collaborators declare that they have no conflicts of interest
A dibenzothiazepine derivative with a novel and distinctive pharmacologic profile is quetiapine The limbic system is overactive in delirium which is one of its pathophysiologies By obstructing the mesolimbic dopamine D2 receptors specifically quetiapine may be able to regulate this hyperactivity
The objective of this study is to compare the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on morbidity length of stay in ICU and mortality in critically ill patients
This research will not receive any grants funding or financial aid NOT FUNDED STUDY Collaborators declare that they have no conflicts of interest
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None